These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 15110026

  • 1. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis.
    Sastre-Garriga J, Ingle GT, Chard DT, Ramió-Torrentà L, Miller DH, Thompson AJ.
    Neuroimage; 2004 May; 22(1):353-9. PubMed ID: 15110026
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.
    Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramió-Torrentà L, Miller DH, Thompson AJ.
    Brain; 2005 Jun; 128(Pt 6):1454-60. PubMed ID: 15817511
    [Abstract] [Full Text] [Related]

  • 4. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.
    Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH.
    Neurology; 2005 Mar 22; 64(6):1001-7. PubMed ID: 15781816
    [Abstract] [Full Text] [Related]

  • 5. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA, Lee JC, Nakamura K, Fisher E.
    J Neurol Sci; 2009 Jul 15; 282(1-2):106-11. PubMed ID: 19100997
    [Abstract] [Full Text] [Related]

  • 6. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O, Gouveia A, Batista S, Moura C, Machado E.
    Neuroradiol J; 2015 Jun 15; 28(3):354-8. PubMed ID: 26246109
    [Abstract] [Full Text] [Related]

  • 7. Volumetric quantitation by MRI in primary progressive multiple sclerosis: volumes of plaques and atrophy correlated with neurological disability.
    Ukkonen M, Dastidar P, Heinonen T, Laasonen E, Elovaara I.
    Eur J Neurol; 2003 Nov 15; 10(6):663-9. PubMed ID: 14641511
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA, Tummala S, Khalid F, Tauhid S, Jalkh Y, Khalil S, Hurwitz S, Zurawski J, Bakshi R.
    J Neurol Sci; 2023 Jan 15; 444():120501. PubMed ID: 36481574
    [Abstract] [Full Text] [Related]

  • 10. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 15; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 11. Gray matter atrophy is related to long-term disability in multiple sclerosis.
    Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH.
    Ann Neurol; 2008 Sep 15; 64(3):247-54. PubMed ID: 18570297
    [Abstract] [Full Text] [Related]

  • 12. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis.
    Tavazzi E, Dwyer MG, Weinstock-Guttman B, Lema J, Bastianello S, Bergamaschi R, Cosi V, Benedict RH, Munschauer FE, Zivadinov R.
    Neuroimage; 2007 Jul 01; 36(3):746-54. PubMed ID: 17498974
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A, Ukmar M, Benedetto Sy, Zorzon M.
    Int Rev Neurobiol; 2007 Jul 01; 79():521-35. PubMed ID: 17531857
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Spinal cord gray matter atrophy correlates with multiple sclerosis disability.
    Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG.
    Ann Neurol; 2014 Oct 01; 76(4):568-80. PubMed ID: 25087920
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.
    Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.
    Mult Scler; 2018 May 01; 24(6):721-727. PubMed ID: 28445084
    [Abstract] [Full Text] [Related]

  • 20. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors.
    Dell'Oglio E, Ceccarelli A, Glanz BI, Healy BC, Tauhid S, Arora A, Saravanan N, Bruha MJ, Vartanian AV, Dupuy SL, Benedict RHB, Bakshi R, Neema M.
    J Neuroimaging; 2015 May 01; 25(2):191-199. PubMed ID: 25523616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.